Literature DB >> 20060328

Immunohistochemical evaluation of three nitric oxide synthase isoforms in human saphenous vein exposed to different degrees of distension pressures.

Fernanda Viaro1, Verena Kise Capellini, Andrea Carla Celotto, Carlos Gilberto Carlotti, Alfredo José Rodrigues, Graziela Saraiva Reis, Viviane dos Santos Augusto, Paulo Roberto Barbosa Evora.   

Abstract

The effect of short duration and different degrees of distension pressures was investigated by means of immunohistochemistry of the three nitric oxide synthase isoforms in the human saphenous vein conventionally harvested from 20 patients submitted to coronary artery bypass graft. The human saphenous vein distal portion was divided into four segments, each one allocated to a different group. In Group I (control group), the human saphenous vein segment was not exposed to distension pressure. In Groups II, III, and IV, the human saphenous vein segment was exposed to 100, 200, and 300 mmHg of distension pressure, respectively. The distension pressures were applied and maintained with Krebs solution for 15 s. The human saphenous vein of the control group presented endothelial nitric oxide synthase and neuronal nitric oxide synthase in both endothelial and smooth muscle cells, while the inducible nitric oxide synthase appeared predominantly in the medial layer. Neither 100 nor 200 mmHg of pressurization affected the immunostaining of any nitric oxide synthase isoform. However, the human saphenous vein segments exposed to 300 mmHg of distension pressure showed a reduction in endothelial nitric oxide synthase content in the endothelium, but not in the tunica media. This lower endothelial nitric oxide synthase immunostaining in the intimal cells was associated with endothelial denudation. Therefore, we conclude that care should be taken when handling the human saphenous vein since just a few seconds of distension pressure above the normal systemic pressure can be sufficient to disrupt the endothelium reducing the amount of endothelial nitric oxide synthase and impairing the graft quality.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060328     DOI: 10.1016/j.carpath.2009.11.002

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  6 in total

1.  Pressure control during preparation of saphenous veins.

Authors:  Fan Dong Li; Susan Eagle; Colleen Brophy; Kyle M Hocking; Michael Osgood; Padmini Komalavilas; Joyce Cheung-Flynn
Journal:  JAMA Surg       Date:  2014-07       Impact factor: 14.766

2.  Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function.

Authors:  Susan Eagle; Colleen M Brophy; Padmini Komalavilas; Kyle Hocking; Gowthami Putumbaka; Michael Osgood; Kevin Sexton; Marzia Leacche; Joyce Cheung-Flynn
Journal:  Am Surg       Date:  2011-07       Impact factor: 0.688

3.  Intimal thickness associated with endothelial dysfunction in human vein grafts.

Authors:  Fan Dong Li; Kevin W Sexton; Kyle M Hocking; Michael J Osgood; Susan Eagle; Joyce Cheung-Flynn; Colleen M Brophy; Padmini Komalavilas
Journal:  J Surg Res       Date:  2012-06-23       Impact factor: 2.192

4.  Endoscopic or No-Touch Vein Harvesting for CABG: What is Best for the Patient?

Authors:  Tomislav Kopjar; Stjepan Ivankovic; Melchior Luiz Lima; Bruno Botelho Pinheiro; Michael Richard Dashwood
Journal:  Braz J Cardiovasc Surg       Date:  2016 Nov-Dec

5.  Adventitial Collagen Cross-Linking by Glutaraldehyde Reinforcing Human Saphenous Vein - Implication for Coronary Artery Bypass Grafting.

Authors:  Changcheng Liu; Duanduan Chen; Zhenfeng Li; Huanming Xu; Chengxiong Gu
Journal:  Braz J Cardiovasc Surg       Date:  2022-08-16

6.  The effect of distension pressure on endothelial injury and vasodilatation response in saphenous vein grafts: conversion of a bypass graft to a dead pipe.

Authors:  Selami Gurkan; Ozcan Gur; Volkan Yuksel; Ebru Tastekin; Serhat Huseyin; Demet Ozkaramanli Gur; Suat Canbaz
Journal:  Kardiochir Torakochirurgia Pol       Date:  2014-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.